- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00872885
Bunionectomy Trial With GRT6005
July 13, 2021 updated by: Tris Pharma, Inc.
A Randomized, Phase IIa Trial Evaluating the Safety and Efficacy of a New Centrally Acting Analgesic in Subjects With Moderate to Severe Pain Following Bunionectomy.
The purpose of the trial is to determine whether the new centrally acting analgesic is effective in comparison to placebo and an active comparator (morphine).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
258
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78705
- Premier Research Group Ltd
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects scheduled to undergo primary unilateral first metatarsal bunionectomy
Exclusion Criteria:
- Contraindications to, or history of allergy or hypersensitivity to morphine, fentanyl, hydrocodone, acetaminophen, heparin, polyethylene glycol 400 USP-NF or any compound planned to be used during the anesthesia, or their excipients.
- Concomitant inflammatory disease.
- Life-long history of seizure disorder or epilepsy.
- Subjects with impaired renal function
- Subjects with impaired hepatic function
- Female subjects who are pregnant or breastfeeding.
- Resting pulse rate is <50bpm or >100 bpm after 5 minutes rest in supine position
- resting blood pressure after 5 minutes rest in supine position: Systolic blood pressure is <100mmHg or >140 mmHg Diastolic blood pressure is <60 mmHg or > 90 mmHg
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: A
Dose 1
|
liquid formulation, 200 to 600 µg, single dose, one day
Other Names:
|
EXPERIMENTAL: B
Dose 2
|
liquid formulation, 200 to 600 µg, single dose, one day
Other Names:
|
EXPERIMENTAL: C
Dose 3
|
liquid formulation, 200 to 600 µg, single dose, one day
Other Names:
|
ACTIVE_COMPARATOR: D
Morphine
|
60 mg
|
PLACEBO_COMPARATOR: E
Placebo
|
single dosage
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Sum of pain intensity 2-10 hours after Investigational medicinal product intake. Pain assessments
Time Frame: 8 hours
|
8 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amount of rescue medication
Time Frame: 24 hours
|
24 hours
|
|
Adverse events
Time Frame: 24 hours
|
Adverse Events reported by the participant as well as electrocardiogram, a measure of electrical activity of the heart and laboratory values
|
24 hours
|
Time to first rescue medication
Time Frame: 24 hours
|
24 hours
|
|
Patient Global Impression of Change
Time Frame: 24 hours
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: John Bothmer, Dr., Grünenthal GmbH
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2009
Primary Completion (ACTUAL)
August 1, 2009
Study Completion (ACTUAL)
October 1, 2009
Study Registration Dates
First Submitted
March 24, 2009
First Submitted That Met QC Criteria
March 30, 2009
First Posted (ESTIMATE)
March 31, 2009
Study Record Updates
Last Update Posted (ACTUAL)
July 15, 2021
Last Update Submitted That Met QC Criteria
July 13, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 425965
- KF5503/37 (OTHER: Sponsor)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post Operative Pain
-
Kaohsiung Medical University Chung-Ho Memorial...Not yet recruitingPostoperative Complications | Chronic Post Operative Pain | Acute Post Operative PainTaiwan
-
MercyOne Des Moines Medical CenterTerminatedPost Operative Pain | Post Operative Nausea and VomitingUnited States
-
E-DA HospitalNot yet recruitingCesarean Section | Post Operative Pain, Acute | Post Operative Pain, ChronicTaiwan
-
University of HaifaRecruiting
-
Hospital Universitari Vall d'Hebron Research InstituteRecruitingPost Operative PainSpain
-
Sohag UniversityNot yet recruitingPost Operative Pain
-
Tribhuvan University Teaching Hospital, Institute...Recruiting
-
Beijing Tide Pharmaceutical Co., LtdThe Third Xiangya Hospital of Central South UniversityNot yet recruitingPain, Post-operativeChina
-
Benaroya Research InstituteRecruitingPost Operative PainUnited States
-
National Cancer Institute, EgyptRecruiting
Clinical Trials on GRT6005
-
Tris Pharma, Inc.CompletedNeoplasms | Pain | Chronic PainAustria, Belgium, Bulgaria, Denmark, Germany, Hungary, Poland, Romania, Serbia, Slovakia
-
Tris Pharma, Inc.Forest LaboratoriesCompletedPain | Diabetic NeuropathiesBulgaria, Germany, Romania
-
Tris Pharma, Inc.Forest LaboratoriesCompletedOsteoarthritis of the KneeAustria, Poland, Spain
-
Tris Pharma, Inc.CompletedDiabetic PolyneuropathyGermany, United Kingdom
-
Tris Pharma, Inc.Forest LaboratoriesCompletedLow Back PainAustria, Belgium, Denmark, Finland, Germany, Hungary, Netherlands, Poland, Spain, Sweden, United Kingdom
-
Tris Pharma, Inc.Forest LaboratoriesCompletedModerate to Severe Chronic Pain Due to Osteoarthritis of the KneeUnited States
-
Tris Pharma, Inc.TerminatedNeoplasms | Pain | Chronic PainCroatia, Austria, Belgium, Bulgaria, Denmark, Germany, Hungary, Poland, Romania, Serbia, Slovakia, Chile, Spain, United Kingdom